Pfizer/Biontech's and Astrazeneca’s Covid-19 vaccines come out strong in an analysis of thousands of UK cases of the Delta variant.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.